FCGRT and myasthenia gravis: As such, the neonatal Fc receptor (FcRn) is now understood to be a crucial potentiator of autoantibody-mediated immune responses, with the first commercial FcRn inhibitor to treat autoimmune diseases such as myasthenia gravis recently having come to market (30, 31).